TDMS Study 05097-02 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest ALPHA-CHLOROACETOPHENONE DATE: 09/13/94
EXPERIMENT: 05097 TEST: 02 TIME: 08:20:46
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01-ES-38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55107
PATHOLOGIST: R. BUSCH CAS: 532-27-4
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest ALPHA-CHLOROACETOPHENONE DATE: 09/13/94
EXPERIMENT: 05097 TEST: 02 TIME: 08:20:46
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55107
PATHOLOGIST: R. BUSCH CAS: 532-27-4
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Clitoral Gland
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Larynx
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest ALPHA-CHLOROACETOPHENONE DATE: 09/13/94
EXPERIMENT: 05097 TEST: 02 TIME: 08:20:46
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55107
PATHOLOGIST: R. BUSCH CAS: 532-27-4
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF ALPHA-CHLOROACETOPHENONE
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hemangiosarcoma
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Mammary Gland Fibroma, Fibroadenoma, Carcinoma, or Adenoma
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
All Organs Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
====================================================================================================
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma: Benign, Complex, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/48 (2%) 0/44 (0%) 2/41 (5%) | 0/44 (0%) 1/38 (3%) 0/39 (0%) |
|ADJUSTED (b) | 3.0% 0.0% 7.1% | 0.0% 4.3% 0.0% |
|TERMINAL (d) | 1/33 (3%) 0/35 (0%) 2/28 (7%) | 0/35 (0%) 1/23 (4%) 0/25 (0%) |
|FIRST INCIDENCE (DAYS) | 736 (T) --- 736 (T) | --- 735 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.315 P=0.488N P=0.442 | P=0.674 P=0.416 (e) |
|INCIDENTAL TUMOR | P=0.315 P=0.488N P=0.442 | P=0.674 P=0.416 (e) |
|LOGISTIC REGRESSION | P=0.315 P=0.488N P=0.442 | P=0.674 P=0.416 (e) |
|COCHRAN-ARMITAGE | P=0.319 | P=0.711 |
|FISHER EXACT | P=0.522N P=0.440 | P=0.463 (e) |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 7/50 (14%) 3/50 (6%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 8.0% 18.8% 9.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/34 (6%) 6/36 (17%) 3/33 (9%) | 0/40 (0%) 0/28 (0%) 0/32 (0%) |
|FIRST INCIDENCE (DAYS) | 666 676 736 (T) | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.547 P=0.171 P=0.642 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.531 P=0.089 P=0.635 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.533 P=0.132 P=0.637 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.571N | (e) |
|FISHER EXACT | P=0.159 P=0.661N | (e) (e) |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 7/50 (14%) 3/50 (6%) | 0/50 (0%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 8.0% 18.8% 9.1% | 0.0% 3.6% 3.1% |
|TERMINAL (d) | 2/34 (6%) 6/36 (17%) 3/33 (9%) | 0/40 (0%) 1/28 (4%) 1/32 (3%) |
|FIRST INCIDENCE (DAYS) | 666 676 736 (T) | --- 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.547 P=0.171 P=0.642 | P=0.289 P=0.429 P=0.455 |
|INCIDENTAL TUMOR | P=0.531 P=0.089 P=0.635 | P=0.289 P=0.429 P=0.455 |
|LOGISTIC REGRESSION | P=0.533 P=0.132 P=0.637 | P=0.289 P=0.429 P=0.455 |
|COCHRAN-ARMITAGE | P=0.571N | P=0.331 |
|FISHER EXACT | P=0.159 P=0.661N | P=0.500 P=0.500 |
|=================================================================================================================================|
| |
|Intestine Small |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 5.6% 0.0% 0.0% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/34 (3%) 0/36 (0%) 0/33 (0%) | 0/40 (0%) 0/28 (0%) 0/32 (0%) |
|FIRST INCIDENCE (DAYS) | 730 --- --- | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.099N P=0.231N P=0.249N | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.127N P=0.362N P=0.265N | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.103N P=0.250N P=0.253N | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.095N | (e) |
|FISHER EXACT | P=0.247N P=0.247N | (e) (e) |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/48 (2%) 4/49 (8%) | 0/50 (0%) 0/49 (0%) 0/49 (0%) |
|ADJUSTED (b) | 0.0% 2.8% 10.5% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/34 (0%) 1/36 (3%) 2/33 (6%) | 0/40 (0%) 0/28 (0%) 0/32 (0%) |
|FIRST INCIDENCE (DAYS) | --- 736 (T) 604 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.025 * P=0.511 P=0.061 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.028 * P=0.511 P=0.069 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.024 * P=0.511 P=0.062 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.025 * | (e) |
|FISHER EXACT | P=0.490 P=0.056 | (e) (e) |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 8/48 (17%) 9/49 (18%) | 4/50 (8%) 8/49 (16%) 3/49 (6%) |
|ADJUSTED (b) | 12.5% 20.1% 22.6% | 10.0% 25.0% 9.4% |
|TERMINAL (d) | 3/34 (9%) 5/36 (14%) 4/33 (12%) | 4/40 (10%) 6/28 (21%) 3/32 (9%) |
|FIRST INCIDENCE (DAYS) | 514 559 339 | 735 (T) 403 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.155 P=0.285 P=0.187 | P=0.550 P=0.066 P=0.621N |
|INCIDENTAL TUMOR | P=0.223 P=0.362 P=0.257 | P=0.543N P=0.092 P=0.621N |
|LOGISTIC REGRESSION | P=0.183 P=0.294 P=0.232 | P=0.490N P=0.160 P=0.621N |
|COCHRAN-ARMITAGE | P=0.152 | P=0.447N |
|FISHER EXACT | P=0.250 P=0.183 | P=0.168 P=0.511N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 12/48 (25%) 12/49 (24%) | 8/50 (16%) 5/49 (10%) 4/49 (8%) |
|ADJUSTED (b) | 25.9% 25.6% 29.0% | 18.3% 14.1% 9.7% |
|TERMINAL (d) | 4/34 (12%) 4/36 (11%) 6/33 (18%) | 5/40 (13%) 2/28 (7%) 1/32 (3%) |
|FIRST INCIDENCE (DAYS) | 535 470 339 | 423 493 382 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.410 P=0.487 P=0.451 | P=0.234N P=0.478N P=0.280N |
|INCIDENTAL TUMOR | P=0.434 P=0.512 P=0.505 | P=0.097N P=0.216N P=0.113N |
|LOGISTIC REGRESSION | P=0.456 P=0.521N P=0.564 | P=0.093N P=0.246N P=0.119N |
|COCHRAN-ARMITAGE | P=0.431 | P=0.143N |
|FISHER EXACT | P=0.455 P=0.478 | P=0.290N P=0.188N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 12/48 (25%) 12/49 (24%) | 8/50 (16%) 6/49 (12%) 4/49 (8%) |
|ADJUSTED (b) | 25.9% 25.6% 29.0% | 18.3% 16.1% 9.7% |
|TERMINAL (d) | 4/34 (12%) 4/36 (11%) 6/33 (18%) | 5/40 (13%) 2/28 (7%) 1/32 (3%) |
|FIRST INCIDENCE (DAYS) | 535 470 339 | 423 493 382 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.410 P=0.487 P=0.451 | P=0.243N P=0.592N P=0.280N |
|INCIDENTAL TUMOR | P=0.434 P=0.512 P=0.505 | P=0.088N P=0.271N P=0.113N |
|LOGISTIC REGRESSION | P=0.456 P=0.521N P=0.564 | P=0.091N P=0.335N P=0.119N |
|COCHRAN-ARMITAGE | P=0.431 | P=0.149N |
|FISHER EXACT | P=0.455 P=0.478 | P=0.403N P=0.188N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 16/50 (32%) 19/48 (40%) 20/49 (41%) | 12/50 (24%) 13/49 (27%) 7/49 (14%) |
|ADJUSTED (b) | 36.0% 39.6% 45.6% | 27.7% 37.0% 18.4% |
|TERMINAL (d) | 7/34 (21%) 8/36 (22%) 10/33 (30%) | 9/40 (23%) 8/28 (29%) 4/32 (13%) |
|FIRST INCIDENCE (DAYS) | 514 470 339 | 423 403 382 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.225 P=0.351 P=0.249 | P=0.298N P=0.210 P=0.295N |
|INCIDENTAL TUMOR | P=0.194 P=0.391 P=0.243 | P=0.154N P=0.434 P=0.149N |
|LOGISTIC REGRESSION | P=0.193 P=0.471 P=0.222 | P=0.123N P=0.509 P=0.144N |
|COCHRAN-ARMITAGE | P=0.211 | P=0.148N |
|FISHER EXACT | P=0.284 P=0.241 | P=0.477 P=0.166N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 16/50 (32%) 19/48 (40%) 20/49 (41%) | 12/50 (24%) 14/49 (29%) 7/49 (14%) |
|ADJUSTED (b) | 36.0% 39.6% 45.6% | 27.7% 38.4% 18.4% |
|TERMINAL (d) | 7/34 (21%) 8/36 (22%) 10/33 (30%) | 9/40 (23%) 8/28 (29%) 4/32 (13%) |
|FIRST INCIDENCE (DAYS) | 514 470 339 | 423 403 382 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.225 P=0.351 P=0.249 | P=0.303N P=0.156 P=0.295N |
|INCIDENTAL TUMOR | P=0.194 P=0.391 P=0.243 | P=0.143N P=0.390 P=0.149N |
|LOGISTIC REGRESSION | P=0.193 P=0.471 P=0.222 | P=0.119N P=0.434 P=0.144N |
|COCHRAN-ARMITAGE | P=0.211 | P=0.151N |
|FISHER EXACT | P=0.284 P=0.241 | P=0.387 P=0.166N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 7/50 (14%) 8/49 (16%) 4/49 (8%) | 4/50 (8%) 1/47 (2%) 5/49 (10%) |
|ADJUSTED (b) | 19.9% 21.0% 11.0% | 9.5% 3.7% 15.6% |
|TERMINAL (d) | 6/34 (18%) 6/36 (17%) 2/33 (6%) | 3/40 (8%) 1/27 (4%) 5/32 (16%) |
|FIRST INCIDENCE (DAYS) | 730 676 661 | 590 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.249N P=0.538 P=0.286N | P=0.313 P=0.291N P=0.371 |
|INCIDENTAL TUMOR | P=0.284N P=0.345 P=0.307N | P=0.347 P=0.206N P=0.435 |
|LOGISTIC REGRESSION | P=0.268N P=0.437 P=0.301N | P=0.347 P=0.208N P=0.423 |
|COCHRAN-ARMITAGE | P=0.238N | P=0.411 |
|FISHER EXACT | P=0.483 P=0.274N | P=0.201N P=0.487 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 3/49 (6%) 9/49 (18%) | 3/50 (6%) 1/47 (2%) 1/49 (2%) |
|ADJUSTED (b) | 17.1% 8.3% 26.0% | 6.9% 3.7% 3.1% |
|TERMINAL (d) | 5/34 (15%) 3/36 (8%) 8/33 (24%) | 1/40 (3%) 1/27 (4%) 1/32 (3%) |
|FIRST INCIDENCE (DAYS) | 730 736 (T) 643 | 590 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.200 P=0.217N P=0.264 | P=0.270N P=0.418N P=0.376N |
|INCIDENTAL TUMOR | P=0.206 P=0.277N P=0.277 | P=0.192N P=0.221N P=0.252N |
|LOGISTIC REGRESSION | P=0.181 P=0.242N P=0.236 | P=0.221N P=0.323N P=0.311N |
|COCHRAN-ARMITAGE | P=0.210 | P=0.209N |
|FISHER EXACT | P=0.254N P=0.274 | P=0.332N P=0.316N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 9/49 (18%) 13/49 (27%) | 6/50 (12%) 2/47 (4%) 6/49 (12%) |
|ADJUSTED (b) | 31.4% 23.6% 35.5% | 14.1% 7.4% 18.8% |
|TERMINAL (d) | 10/34 (29%) 7/36 (19%) 10/33 (30%) | 4/40 (10%) 2/27 (7%) 6/32 (19%) |
|FIRST INCIDENCE (DAYS) | 730 676 643 | 590 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.326 P=0.355N P=0.372 | P=0.424 P=0.273N P=0.468 |
|INCIDENTAL TUMOR | P=0.307 P=0.524N P=0.370 | P=0.474 P=0.156N P=0.550 |
|LOGISTIC REGRESSION | P=0.288 P=0.469N P=0.329 | P=0.464 P=0.183N P=0.524 |
|COCHRAN-ARMITAGE | P=0.339 | P=0.555 |
|FISHER EXACT | P=0.421N P=0.385 | P=0.155N P=0.606 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 4/50 (8%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 10.0% 3.3% 2.3% |
|TERMINAL (d) | 0/34 (0%) 0/36 (0%) 0/33 (0%) | 4/40 (10%) 0/28 (0%) 0/32 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 735 (T) 720 583 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.154N P=0.299N P=0.245N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.098N P=0.217N P=0.167N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.115N P=0.269N P=0.190N |
|COCHRAN-ARMITAGE | (e) | P=0.101N |
|FISHER EXACT | (e) (e) | P=0.181N P=0.181N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 5/50 (10%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 12.5% 3.3% 2.3% |
|TERMINAL (d) | 0/34 (0%) 0/36 (0%) 0/33 (0%) | 5/40 (13%) 0/28 (0%) 0/32 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 735 (T) 720 583 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.086N P=0.202N P=0.156N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.051N P=0.142N P=0.103N |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.060N P=0.177N P=0.117N |
|COCHRAN-ARMITAGE | (e) | P=0.049N* |
|FISHER EXACT | (e) (e) | P=0.102N P=0.102N |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/44 (0%) 1/37 (3%) 0/46 (0%) | 20/45 (44%) 15/43 (35%) 12/45 (27%) |
|ADJUSTED (b) | 0.0% 3.3% 0.0% | 52.4% 54.7% 35.6% |
|TERMINAL (d) | 0/33 (0%) 1/30 (3%) 0/31 (0%) | 18/36 (50%) 12/24 (50%) 9/30 (30%) |
|FIRST INCIDENCE (DAYS) | --- 736 (T) --- | 715 685 646 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.719 P=0.481 (e) | P=0.178N P=0.431 P=0.190N |
|INCIDENTAL TUMOR | P=0.719 P=0.481 (e) | P=0.094N P=0.486N P=0.100N |
|LOGISTIC REGRESSION | P=0.719 P=0.481 (e) | P=0.113N P=0.567 P=0.119N |
|COCHRAN-ARMITAGE | P=0.718N | P=0.049N* |
|FISHER EXACT | P=0.457 (e) | P=0.243N P=0.061N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/44 (0%) 1/37 (3%) 0/46 (0%) | 20/45 (44%) 15/43 (35%) 13/45 (29%) |
|ADJUSTED (b) | 0.0% 3.3% 0.0% | 52.4% 54.7% 37.1% |
|TERMINAL (d) | 0/33 (0%) 1/30 (3%) 0/31 (0%) | 18/36 (50%) 12/24 (50%) 9/30 (30%) |
|FIRST INCIDENCE (DAYS) | --- 736 (T) --- | 715 685 583 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.719 P=0.481 (e) | P=0.244N P=0.431 P=0.262N |
|INCIDENTAL TUMOR | P=0.719 P=0.481 (e) | P=0.134N P=0.486N P=0.135N |
|LOGISTIC REGRESSION | P=0.719 P=0.481 (e) | P=0.151N P=0.567 P=0.158N |
|COCHRAN-ARMITAGE | P=0.718N | P=0.077N |
|FISHER EXACT | P=0.457 (e) | P=0.243N P=0.095N |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Carcinoma or Papilloma Squamous |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 0/50 (0%) | 1/50 (2%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | 5.9% 2.6% 0.0% | 2.2% 3.6% 6.3% |
|TERMINAL (d) | 2/34 (6%) 0/36 (0%) 0/33 (0%) | 0/40 (0%) 1/28 (4%) 2/32 (6%) |
|FIRST INCIDENCE (DAYS) | 736 (T) 676 --- | 647 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.149N P=0.495N P=0.245N | P=0.314 P=0.704 P=0.426 |
|INCIDENTAL TUMOR | P=0.171N P=0.624N P=0.245N | P=0.333 P=0.723N P=0.469 |
|LOGISTIC REGRESSION | P=0.150N P=0.517N P=0.245N | P=0.347 P=0.765N P=0.482 |
|COCHRAN-ARMITAGE | P=0.142N | P=0.378 |
|FISHER EXACT | P=0.500N P=0.247N | P=0.753N P=0.500 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 0/50 (0%) | 0/50 (0%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | 5.9% 2.6% 0.0% | 0.0% 3.6% 6.3% |
|TERMINAL (d) | 2/34 (6%) 0/36 (0%) 0/33 (0%) | 0/40 (0%) 1/28 (4%) 2/32 (6%) |
|FIRST INCIDENCE (DAYS) | 736 (T) 676 --- | --- 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.149N P=0.495N P=0.245N | P=0.115 P=0.429 P=0.191 |
|INCIDENTAL TUMOR | P=0.171N P=0.624N P=0.245N | P=0.115 P=0.429 P=0.191 |
|LOGISTIC REGRESSION | P=0.150N P=0.517N P=0.245N | P=0.115 P=0.429 P=0.191 |
|COCHRAN-ARMITAGE | P=0.142N | P=0.142 |
|FISHER EXACT | P=0.500N P=0.247N | P=0.500 P=0.247 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/45 (2%) 1/48 (2%) | 0/49 (0%) 0/46 (0%) 2/49 (4%) |
|ADJUSTED (b) | 0.0% 2.8% 3.0% | 0.0% 0.0% 6.3% |
|TERMINAL (d) | 0/34 (0%) 1/36 (3%) 1/33 (3%) | 0/40 (0%) 0/27 (0%) 2/32 (6%) |
|FIRST INCIDENCE (DAYS) | --- 736 (T) 736 (T) | --- --- 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.324 P=0.511 P=0.494 | P=0.082 (e) P=0.191 |
|INCIDENTAL TUMOR | P=0.324 P=0.511 P=0.494 | P=0.082 (e) P=0.191 |
|LOGISTIC REGRESSION | P=0.324 P=0.511 P=0.494 | P=0.082 (e) P=0.191 |
|COCHRAN-ARMITAGE | P=0.325 | P=0.098 |
|FISHER EXACT | P=0.474 P=0.490 | (e) P=0.247 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 3/50 (6%) 2/50 (4%) 2/50 (4%) |
|ADJUSTED (b) | | 7.5% 6.9% 6.3% |
|TERMINAL (d) | | 3/40 (8%) 1/28 (4%) 2/32 (6%) |
|FIRST INCIDENCE (DAYS) | | 735 (T) 722 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.509N P=0.655N P=0.602N |
|INCIDENTAL TUMOR | | P=0.488N P=0.562N P=0.602N |
|LOGISTIC REGRESSION | | P=0.508N P=0.632N P=0.602N |
|COCHRAN-ARMITAGE | | P=0.406N |
|FISHER EXACT | | P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 4/50 (8%) | 0/50 (0%) 2/50 (4%) 2/50 (4%) |
|ADJUSTED (b) | 2.9% 2.8% 10.5% | 0.0% 6.4% 5.2% |
|TERMINAL (d) | 1/34 (3%) 1/36 (3%) 2/33 (6%) | 0/40 (0%) 1/28 (4%) 1/32 (3%) |
|FIRST INCIDENCE (DAYS) | 736 (T) 736 (T) 604 | --- 685 472 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.096 P=0.749N P=0.172 | P=0.147 P=0.177 P=0.211 |
|INCIDENTAL TUMOR | P=0.111 P=0.749N P=0.204 | P=0.182 P=0.277 P=0.267 |
|LOGISTIC REGRESSION | P=0.097 P=0.749N P=0.178 | P=0.192 P=0.217 P=0.309 |
|COCHRAN-ARMITAGE | P=0.101 | P=0.176 |
|FISHER EXACT | P=0.753N P=0.181 | P=0.247 P=0.247 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 4/50 (8%) | 0/50 (0%) 2/50 (4%) 2/50 (4%) |
|ADJUSTED (b) | 5.9% 2.8% 10.5% | 0.0% 6.4% 5.2% |
|TERMINAL (d) | 2/34 (6%) 1/36 (3%) 2/33 (6%) | 0/40 (0%) 1/28 (4%) 1/32 (3%) |
|FIRST INCIDENCE (DAYS) | 736 (T) 736 (T) 604 | --- 685 472 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.228 P=0.480N P=0.323 | P=0.147 P=0.177 P=0.211 |
|INCIDENTAL TUMOR | P=0.250 P=0.480N P=0.365 | P=0.182 P=0.277 P=0.267 |
|LOGISTIC REGRESSION | P=0.227 P=0.480N P=0.329 | P=0.192 P=0.217 P=0.309 |
|COCHRAN-ARMITAGE | P=0.238 | P=0.176 |
|FISHER EXACT | P=0.500N P=0.339 | P=0.247 P=0.247 |
|=================================================================================================================================|
| |
|All Organs |
| Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 1/50 (2%) 0/50 (0%) 3/50 (6%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 2.5% 0.0% 8.0% |
|TERMINAL (d) | 0/34 (0%) 0/36 (0%) 0/33 (0%) | 1/40 (3%) 0/28 (0%) 0/32 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 735 (T) --- 641 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.144 P=0.571N P=0.243 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.206 P=0.571N P=0.410 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.177 P=0.571N P=0.317 |
|COCHRAN-ARMITAGE | (e) | P=0.176 |
|FISHER EXACT | (e) (e) | P=0.500N P=0.309 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 6/50 (12%) 8/50 (16%) | 23/50 (46%) 19/50 (38%) 16/50 (32%) |
|ADJUSTED (b) | 14.0% 15.1% 20.6% | 50.9% 52.7% 44.1% |
|TERMINAL (d) | 2/34 (6%) 3/36 (8%) 5/33 (15%) | 18/40 (45%) 12/28 (43%) 12/32 (38%) |
|FIRST INCIDENCE (DAYS) | 520 559 182 | 473 371 641 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.307 P=0.596 P=0.361 | P=0.340N P=0.400 P=0.358N |
|INCIDENTAL TUMOR | P=0.406 P=0.490 P=0.444 | P=0.146N P=0.331N P=0.175N |
|LOGISTIC REGRESSION | P=0.440 P=0.591 P=0.543 | P=0.146N P=0.341N P=0.182N |
|COCHRAN-ARMITAGE | P=0.330 | P=0.091N |
|FISHER EXACT | P=0.620N P=0.387 | P=0.272N P=0.109N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 6/50 (12%) 8/50 (16%) | 22/50 (44%) 19/50 (38%) 13/50 (26%) |
|ADJUSTED (b) | 14.0% 15.1% 20.6% | 48.6% 52.7% 39.2% |
|TERMINAL (d) | 2/34 (6%) 3/36 (8%) 5/33 (15%) | 17/40 (43%) 12/28 (43%) 12/32 (38%) |
|FIRST INCIDENCE (DAYS) | 520 559 182 | 473 371 673 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.307 P=0.596 P=0.361 | P=0.191N P=0.342 P=0.189N |
|INCIDENTAL TUMOR | P=0.406 P=0.490 P=0.444 | P=0.077N P=0.394N P=0.104N |
|LOGISTIC REGRESSION | P=0.440 P=0.591 P=0.543 | P=0.069N P=0.412N P=0.091N |
|COCHRAN-ARMITAGE | P=0.330 | P=0.038N* |
|FISHER EXACT | P=0.620N P=0.387 | P=0.342N P=0.046N* |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 17/50 (34%) 21/50 (42%) 17/50 (34%) | 29/50 (58%) 24/50 (48%) 24/50 (48%) |
|ADJUSTED (b) | 43.7% 51.1% 42.7% | 67.4% 72.2% 68.4% |
|TERMINAL (d) | 13/34 (38%) 16/36 (44%) 11/33 (33%) | 26/40 (65%) 19/28 (68%) 21/32 (66%) |
|FIRST INCIDENCE (DAYS) | 514 559 339 | 590 403 646 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.488 P=0.317 P=0.529 | P=0.462 P=0.277 P=0.518 |
|INCIDENTAL TUMOR | P=0.496N P=0.220 P=0.541N | P=0.493N P=0.584 P=0.524N |
|LOGISTIC REGRESSION | P=0.493 P=0.212 P=0.568 | P=0.485N P=0.559N P=0.518N |
|COCHRAN-ARMITAGE | P=0.541N | P=0.184N |
|FISHER EXACT | P=0.268 P=0.583N | P=0.212N P=0.212N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 23/50 (46%) 23/50 (46%) 29/50 (58%) | 30/50 (60%) 29/50 (58%) 25/50 (50%) |
|ADJUSTED (b) | 52.7% 48.3% 64.7% | 61.2% 67.8% 58.9% |
|TERMINAL (d) | 14/34 (41%) 12/36 (33%) 18/33 (55%) | 21/40 (53%) 15/28 (54%) 15/32 (47%) |
|FIRST INCIDENCE (DAYS) | 520 470 182 | 423 371 382 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.143 P=0.555N P=0.160 | P=0.487 P=0.165 P=0.543 |
|INCIDENTAL TUMOR | P=0.183 P=0.525N P=0.213 | P=0.138N P=0.319N P=0.159N |
|LOGISTIC REGRESSION | P=0.194 P=0.434N P=0.217 | P=0.141N P=0.466N P=0.194N |
|COCHRAN-ARMITAGE | P=0.136 | P=0.182N |
|FISHER EXACT | P=0.579N P=0.158 | P=0.500N P=0.211N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05097 TEST: 02 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- ALPHA-CHLOROACETOPHENONE
MALE TERMINAL SACRIFICE AT 106 WEEKS
FEMALE TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 2 MG/M3 4 MG/M3 | CONTROL 2 MG/M3 4 MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 33/50 (66%) 35/50 (70%) 39/50 (78%) | 42/50 (84%) 40/50 (80%) 38/50 (76%) |
|ADJUSTED (b) | 72.8% 71.4% 82.7% | 85.7% 90.6% 88.2% |
|TERMINAL (d) | 22/34 (65%) 22/36 (61%) 25/33 (76%) | 33/40 (83%) 24/28 (86%) 27/32 (84%) |
|FIRST INCIDENCE (DAYS) | 514 470 182 | 423 371 382 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.140 P=0.474 P=0.153 | P=0.248 P=0.061 P=0.286 |
|INCIDENTAL TUMOR | P=0.150 P=0.564 P=0.165 | P=0.309N P=0.497N P=0.372N |
|LOGISTIC REGRESSION | P=0.148 P=0.517 P=0.171 | P=0.288N P=0.484N P=0.358N |
|COCHRAN-ARMITAGE | P=0.112 | P=0.191N |
|FISHER EXACT | P=0.415 P=0.133 | P=0.398N P=0.227N |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 106929-106929/106929
--multipart-boundary--